News headlines about Transenterix (NYSE:TRXC) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Transenterix earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 45.4055258838946 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s analysis:

Shares of Transenterix (NYSE TRXC) opened at 3.69 on Thursday. The company’s market cap is $548.10 million. Transenterix has a 1-year low of $0.45 and a 1-year high of $4.49. The company has a 50-day moving average of $1.49 and a 200-day moving average of $0.92.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.watchlistnews.com/transenterix-trxc-getting-somewhat-positive-media-coverage-study-shows/1640462.html.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

Insider Buying and Selling by Quarter for Transenterix (NYSE:TRXC)

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.